SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Hippieslayer who wrote (19409)4/22/1998 2:38:00 PM
From: Henry Niman  Respond to of 32384
 
I don't believe that Idoxifene has been entered into a breast cancer prevention trial and I have not heard it mentioned in any of the news stories on breast cancer prevention. Since Evista (Raloxifene) is slated to go head to head against Tamoxifen in the next NCI prevention trial, virtually all reports mention just those two compounds.



To: Hippieslayer who wrote (19409)4/22/1998 2:42:00 PM
From: bob smith  Respond to of 32384
 
Who is doing all this dumping today??

It seems to be unnoticed here...



To: Hippieslayer who wrote (19409)4/22/1998 2:43:00 PM
From: tonyt  Respond to of 32384
 
>NO

Hmmmm.... More misinformation??????



To: Hippieslayer who wrote (19409)4/22/1998 2:56:00 PM
From: Henry Niman  Read Replies (1) | Respond to of 32384
 
I guess even the press must be conspiring to put out good news on LGND. Maybe that's who's buying the blocks ABOVE the ask price.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News